Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FDA approval summary for lonafarnib (Zokinvy) for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies

12 Dec 2022

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Nuclear Structure and Function
Share to PARP inhibition in cancer therapy

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 36507973
DOI: 10.1016/j.gim.2022.11.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FDA approval summary for lonafarnib (Zokinvy) for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathiesPMID 36507973Read ↗

Small-Molecule Therapeutic Perspectives for the Treatment of Progeria.Semantic proximity Read ↗

Lonafarnib: First ApprovalSemantic proximity Read ↗

Hutchinson-Gilford Progeria paves the way for novel targeted anti-aging therapies.Semantic proximity Read ↗

An overview of treatment strategies for Hutchinson-Gilford Progeria syndrome.Semantic proximity Read ↗

Pharmacotherapy to gene editing: potential therapeutic approaches for Hutchinson-Gilford progeria syndrome.Semantic proximity Read ↗

The farnesyl transferase inhibitor (FTI) lonafarnib improves nuclear morphology in ZMPSTE24-deficient fibroblasts from patients with the progeroid disorder MAD-B.Semantic proximity Read ↗

Hutchinson-Gilford Progeria Syndrome: An Overview of the Molecular Mechanism, Pathophysiology and Therapeutic Approach.Semantic proximity Read ↗

Isoprenylcysteine Carboxylmethyltransferase-Based Therapy for Hutchinson–Gilford Progeria SyndromeSemantic proximity Read ↗

Hutchinson-Gilford Progeria Syndrome—Current Status and Prospects for Gene Therapy TreatmentSemantic proximity Read ↗

Unraveling the mysteries of Hutchinson-Gilford progeria syndrome: a comprehensive review of LMNA gene mutations.Semantic proximity Read ↗

Hutchinson-Gilford Progeria Syndrome: A Literature ReviewSemantic proximity Read ↗

Mini-Review: molecular elucidations of hutchinson-gilford progeria syndrome: A hope for managing horrors of premature aging in children.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.